{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:43:37Z","timestamp":1784202217784,"version":"3.55.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bioorg.2021.105461","type":"journal-article","created":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T10:50:59Z","timestamp":1635677459000},"page":"105461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["\u03b2-Carboline tethered cinnamoyl 2-aminobenzamides as class I selective HDAC inhibitors: Design, synthesis, biological activities and modelling studies"],"prefix":"10.1016","volume":"117","author":[{"given":"Hari Krishna","family":"Namballa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratibha","family":"Anchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kesari","family":"Lakshmi Manasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay Prakash","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandraiah","family":"Godugu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagula","family":"Shankaraiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2021.105461_h0005","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: a review and synthetic analysis","volume":"13","author":"De Martel","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2021.105461_h0010","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.bioorg.2021.105461_h0015","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1126\/science.3310230","article-title":"The inheritance of epigenetic defects","volume":"238","author":"Holliday","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2021.105461_h0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","article-title":"Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials","volume":"4","author":"Cheng","year":"2019","journal-title":"Sig. Transduct. Target Ther."},{"key":"10.1016\/j.bioorg.2021.105461_h0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.0030157","article-title":"Comparing the DNA hypermethylome with gene mutations in human colorectal cancer","volume":"3","author":"Schuebel","year":"2007","journal-title":"PLoS Genet."},{"key":"10.1016\/j.bioorg.2021.105461_h0030","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nrc3130","article-title":"A decade of exploring the cancer epigenome - biological and translational implications","volume":"11","author":"Baylin","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2021.105461_h0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2021.105461_h0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-020-01197-3","article-title":"Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy","volume":"19","author":"Lu","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2021.105461_h0045","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.1175371","article-title":"Lysine acetylation targets protein complexes and co-regulates major cellular functions","volume":"325","author":"Choudhary","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2021.105461_h0050","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.3748\/wjg.v24.i41.4635","article-title":"Concept of histone deacetylases in cancer: reflections on esophageal carcinogenesis and treatment","volume":"24","author":"Schizas","year":"2018","journal-title":"World j. gastroenterol."},{"key":"10.1016\/j.bioorg.2021.105461_h0055","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2353\/ajpath.2009.081142","article-title":"Epigenetic dysregulation in cancer","volume":"175","author":"Muntean","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bioorg.2021.105461_h0060","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1039\/D0MD00286K","article-title":"Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6","volume":"12","author":"Chan","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_h0065","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1177\/1535370220928278","article-title":"Histone deacetylase-3: friend and foe of the brain","volume":"245","author":"D\u2019Mello","year":"2020","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.bioorg.2021.105461_h0070","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2021.105461_h0075","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3390\/cells9030780","article-title":"Role of histone deacetylases in carcinogenesis: potential role in cholangiocarcinoma","volume":"9","author":"Pant","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2021.105461_h0080","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1128\/MCB.25.8.2873-2884.2005","article-title":"Class II histone deacetylases: from sequence to function, regulation, and clinical implication","volume":"25","author":"Yang","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bioorg.2021.105461_h0085","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1139\/o01-116","article-title":"The emerging role of class II histone deacetylases","volume":"79","author":"Fischle","year":"2001","journal-title":"Biochem. Cell Biol."},{"key":"10.1016\/j.bioorg.2021.105461_h0090","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/febs.13061","article-title":"Class IIa HDACs \u2013 new insights into their functions in physiology and pathology","volume":"282","author":"Parra","year":"2015","journal-title":"FEBS J."},{"key":"10.1016\/j.bioorg.2021.105461_b0040","doi-asserted-by":"crossref","unstructured":"(a) A.R. Guardiola, T.-P. Yao, Molecular cloning and characterization of a novel histone deacetylase HDAC10, J. Biol. Chem. 277 (2002) 3350-3356. b) K. Xiong H. Zhang, Y. Du, J. Tian, S. Ding, Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer, Exp. Mol. Med. 51 (2019) 1\u201315.","DOI":"10.1038\/s12276-019-0301-8"},{"key":"10.1016\/j.bioorg.2021.105461_b0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/hepr.12757","article-title":"Histone deacetylases function as novel potential therapeutic targets for cancer","volume":"47","author":"Zhang","year":"2017","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.bioorg.2021.105461_h0105","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2021.105461_h0110","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3390\/ijms20071616","article-title":"Mechanism of action for HDAC inhibitors \u2013 insights from omics approaches","volume":"20","author":"Li","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2021.105461_h0115","first-page":"769","article-title":"Expression profile of class I histone deacetylases in human cancer tissues","volume":"18","author":"Nakagawa","year":"2007","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bioorg.2021.105461_h0120","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/cas.13062","article-title":"Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies","volume":"107","author":"Imai","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bioorg.2021.105461_h0125","first-page":"481","article-title":"HDAC inhibitor-induced mitotic arrest is mediated by Eg5\/KIF11 acetylation, Cell","volume":"24","author":"Nalawansha","year":"2017","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2021.105461_h0130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/bs.acr.2018.02.006","article-title":"Advances and challenges of HDAC inhibitors in cancer therapeutics","volume":"138","author":"McClure","year":"2018","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.bioorg.2021.105461_b0065","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1158\/1078-0432.CCR-04-2088","article-title":"Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity","volume":"11","author":"Munshi","year":"2005","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.bioorg.2021.105461_b0070","doi-asserted-by":"crossref","first-page":"823","DOI":"10.4161\/cbt.8.9.8143","article-title":"Sensitization to \u03b3-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells","volume":"8","author":"Zhang","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bioorg.2021.105461_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011208","article-title":"Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor","volume":"5","author":"Kachhap","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bioorg.2021.105461_b0080","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1158\/0008-5472.CAN-15-2680","article-title":"Enhanced histone deacetylase activity in malignant melanoma provokes RAD51 and FANCD2-triggered drug resistance","volume":"76","author":"Krumm","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2021.105461_b0085","doi-asserted-by":"crossref","first-page":"9214","DOI":"10.1021\/acs.jmedchem.5b01052","article-title":"Novel \u03b2-carboline\/hydroxamic acid hybrids targeting both histone deacetylase and DNA display high anticancer activity via regulation of the p53 signaling pathway","volume":"58","author":"Ling","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_b0090","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/cmdc.201700133","article-title":"Design and synthesis of C3-substituted \u03b2-carboline-based histone deacetylase inhibitors with potent antitumor activities","volume":"12","author":"Ling","year":"2017","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_b0095","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-Cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.bioorg.2021.105461_b0100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1188\/12.CJON.195-204","article-title":"Romidepsin: A new drug for the treatment of cutaneous T-Cell lymphoma","volume":"16","author":"Frye","year":"2012","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.bioorg.2021.105461_b0105","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA approval: Belinostat for the treatment of patients with pelapsed or refractory peripheral T-cell lymphoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2021.105461_b0110","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","article-title":"Panobinostat for the treatment of multiple myeloma","volume":"21","author":"Laubach","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2021.105461_b0115","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.ejmech.2010.02.030","article-title":"Inside HDAC with HDAC inhibitors","volume":"45","author":"Bertrand","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_b0120","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.bjc.6604199","article-title":"Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy","volume":"98","author":"Weichert","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2021.105461_b0125","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1158\/1078-0432.CCR-07-0990","article-title":"Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: Specific role of class I histone deacetylases in vitro and in vivo","volume":"14","author":"Weichert","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2021.105461_b0130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000111106","article-title":"Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma","volume":"72","author":"Rikimaru","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.bioorg.2021.105461_b0135","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MPA.0b013e31815f2c2a","article-title":"Expression of hypoxia-inducible factor-1\u03b1, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma","volume":"36","author":"Miyake","year":"2008","journal-title":"Pancreas"},{"key":"10.1016\/j.bioorg.2021.105461_h0210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","article-title":"The role of histone deacetylases (HDACs) in human cancer","volume":"1","author":"Ropero","year":"2007","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bioorg.2021.105461_h0215","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Lane","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2021.105461_b0145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2227","article-title":"Vorinostat","volume":"6","author":"Grant","year":"2007","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.bioorg.2021.105461_b0150","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2021.105461_b0155","doi-asserted-by":"crossref","first-page":"7672","DOI":"10.1021\/acs.jmedchem.5b01044","article-title":"Discovery of novel class I histone deacetylase inhibitors with promising in vitro and in vivo antitumor activities","volume":"58","author":"Yao","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_b0160","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.leu.2404464","article-title":"Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?","volume":"21","author":"Karagiannis","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2021.105461_b0165","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1016\/j.bmc.2012.04.032","article-title":"Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors","volume":"20","author":"Guan","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_b0170","first-page":"5766","article-title":"Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif Bioorg","volume":"22","author":"Guan","year":"2014","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_b0175","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1016\/j.bmc.2015.07.008","article-title":"Design, synthesis and biological evaluation of saccharin-based N-hydroxybenzamides as histone deacetylases (HDACs) inhibitors","volume":"23","author":"Fu","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_b0180","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.bmc.2016.02.005","article-title":"Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors","volume":"24","author":"Liu","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_b0185","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1039\/C4MD00203B","article-title":"Design, synthesis, and preliminary bioactivity studies of substituted purine hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors","volume":"5","author":"Wang","year":"2014","journal-title":"MedChemComm"},{"key":"10.1016\/j.bioorg.2021.105461_b0190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejmech.2017.03.064","article-title":"Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors","volume":"133","author":"Chen","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2015.12.033","article-title":"Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC","volume":"109","author":"Peng","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_b0200","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1016\/j.bmc.2015.06.024","article-title":"Design, synthesis and preliminary bioactivity evaluations of substituted quinoline hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors","volume":"23","author":"Wang","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_b0205","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1016\/j.bmc.2018.08.031","article-title":"Synthesis of DNA interactive C3-trans-cinnamide linked \u03b2-carboline conjugates as potential cytotoxic and DNA topoisomerase I inhibitors","volume":"26","author":"Sathish","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104481","volume":"106","author":"Tokala","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104357","volume":"105","author":"Tokala","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_b0220","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/cmdc.201800402","article-title":"Design and synthesis of DNA-interactive \u03b2-carboline-oxindole hybrids as cytotoxic and apoptosis inducing agents","volume":"13","author":"Tokala","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2021.105461_b0225","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bioorg.2015.11.005","article-title":"Design and synthesis of C3-tethered 1,2,3-triazolo-\u03b2-carboline derivatives: Anticancer activity, DNA-binding ability, viscosity and molecular modeling studies","volume":"64","author":"Shankaraiah","year":"2016","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_b0230","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ejmech.2017.12.055","article-title":"Synthesis of podophyllotoxin linked \u03b2-carboline congeners as potential anticancer agents and DNA topoisomerase II inhibitors","volume":"144","author":"Sathish","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_b0235","doi-asserted-by":"crossref","first-page":"16226","DOI":"10.1039\/C8NJ03248C","article-title":"Synthesis and in vitro cytotoxicity evaluation of \u03b2-carboline-linked 2,4-thiazolidinedione hybrids: potential DNA intercalation and apoptosis-inducing studies","volume":"42","author":"Tokala","year":"2018","journal-title":"New J. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_b0240","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bioorg.2015.02.007","article-title":"DNA-binding affinity and anticancer activity of \u03b2-carboline\u2013chalcone conjugates as potential DNA intercalators: Molecular modelling and synthesis","volume":"59","author":"Shankaraiah","year":"2015","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_b0245","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1039\/D0MD00422G","article-title":"\u03b2-Carboline-based molecular hybrids as anticancer agents: a brief sketch","volume":"12","author":"Soni","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_b0250","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4155\/fmc.12.190","article-title":"Targeting cancer cell mitochondria as a therapeutic approach","volume":"5","author":"Wen","year":"2013","journal-title":"Fut. Med Chem."},{"key":"10.1016\/j.bioorg.2021.105461_h0330","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.7164\/antibiotics.53.1191","article-title":"Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells","volume":"53","author":"Kim","year":"2000","journal-title":"J. Antibiot."},{"key":"10.1016\/j.bioorg.2021.105461_h0335","doi-asserted-by":"crossref","first-page":"21040","DOI":"10.1074\/jbc.M511059200","article-title":"G1\/S arrest induced by histone deacetylase inhibitor sodium butyrate in E1A + ras-transformed cells is mediated through down-regulation of E2F activity and stabilization of \u03b2-catenin","volume":"281","author":"Abramova","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2021.105461_h0340","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1158\/1535-7163.MCT-04-0107","article-title":"Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad","volume":"4","author":"Strait","year":"2005","journal-title":"Mol. Cancer. Ther."},{"key":"10.1016\/j.bioorg.2021.105461_b0260","unstructured":"Schr\u00f6dinger suite 2014-3; Schr\u00f6dinger, LLC: New York, 2014."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821008397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821008397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:28:23Z","timestamp":1758616103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206821008397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":69,"alternative-id":["S0045206821008397"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105461","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03b2-Carboline tethered cinnamoyl 2-aminobenzamides as class I selective HDAC inhibitors: Design, synthesis, biological activities and modelling studies","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105461","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105461"}}